Loading…

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2011-09, Vol.34 (5), p.586-586
Main Authors: Deshpande, A. R., Strobel, S.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3698-d10f15bb772e054d985a838166fe9b49ba813e6b3eeb69fa02cad299ed02abaa3
cites
container_end_page 586
container_issue 5
container_start_page 586
container_title Alimentary pharmacology & therapeutics
container_volume 34
creator Deshpande, A. R.
Strobel, S.
description
doi_str_mv 10.1111/j.1365-2036.2011.04778.x
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_880998547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>880998547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3698-d10f15bb772e054d985a838166fe9b49ba813e6b3eeb69fa02cad299ed02abaa3</originalsourceid><addsrcrecordid>eNo9kU1OwzAQhS0EoqVwBeQdqwTbSRwbiUVV8SdVoouytux4oqZKkxCntN1xDa7HSXDaUmusGWk-jzzvIYQpCak_98uQRjwJGIl4yAilIYnTVITbMzQ8Nc7RkDAuAyZoNEBXzi0JITwl7BINGBWE8zgdomrWgi2yrqgrXOd40taL6vf7x2FbONAOcAulbnzeFN0C5xoyXWJ_m7buwD-r8D7ystgWK2087pq6stC6B6yxp1zTY1-AXbe2u2t0kevSwc0xj9DH89N88hpM31_eJuNpkEVcisBSktPEmDRlQJLYSpFoEQnKeQ7SxNJovxRwEwEYLnNNWKYtkxIsYdpoHY3Q3WGu_8HnGlynVoXLoCx1BfXaKSGI9EPj1JO3R3JtVmBV0_o92p36l8gDjwdgU5SwO_UpUb0Vaql6xVWvuOqtUHsr1FaNZ_O-iv4AObN_zQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>880998547</pqid></control><display><type>article</type><title>Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study</title><source>Wiley</source><creator>Deshpande, A. R. ; Strobel, S.</creator><creatorcontrib>Deshpande, A. R. ; Strobel, S.</creatorcontrib><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2011.04778.x</identifier><identifier>PMID: 21806647</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Crohn Disease - diagnosis ; Feces - chemistry ; Female ; Gastrointestinal Agents - therapeutic use ; Humans ; Leukocyte L1 Antigen Complex - metabolism ; Male ; Tumor Necrosis Factor-alpha - therapeutic use</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2011-09, Vol.34 (5), p.586-586</ispartof><rights>2011 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3698-d10f15bb772e054d985a838166fe9b49ba813e6b3eeb69fa02cad299ed02abaa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21806647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deshpande, A. R.</creatorcontrib><creatorcontrib>Strobel, S.</creatorcontrib><title>Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Crohn Disease - diagnosis</subject><subject>Feces - chemistry</subject><subject>Female</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>Leukocyte L1 Antigen Complex - metabolism</subject><subject>Male</subject><subject>Tumor Necrosis Factor-alpha - therapeutic use</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNo9kU1OwzAQhS0EoqVwBeQdqwTbSRwbiUVV8SdVoouytux4oqZKkxCntN1xDa7HSXDaUmusGWk-jzzvIYQpCak_98uQRjwJGIl4yAilIYnTVITbMzQ8Nc7RkDAuAyZoNEBXzi0JITwl7BINGBWE8zgdomrWgi2yrqgrXOd40taL6vf7x2FbONAOcAulbnzeFN0C5xoyXWJ_m7buwD-r8D7ystgWK2087pq6stC6B6yxp1zTY1-AXbe2u2t0kevSwc0xj9DH89N88hpM31_eJuNpkEVcisBSktPEmDRlQJLYSpFoEQnKeQ7SxNJovxRwEwEYLnNNWKYtkxIsYdpoHY3Q3WGu_8HnGlynVoXLoCx1BfXaKSGI9EPj1JO3R3JtVmBV0_o92p36l8gDjwdgU5SwO_UpUb0Vaql6xVWvuOqtUHsr1FaNZ_O-iv4AObN_zQ</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Deshpande, A. R.</creator><creator>Strobel, S.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study</title><author>Deshpande, A. R. ; Strobel, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3698-d10f15bb772e054d985a838166fe9b49ba813e6b3eeb69fa02cad299ed02abaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Crohn Disease - diagnosis</topic><topic>Feces - chemistry</topic><topic>Female</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>Leukocyte L1 Antigen Complex - metabolism</topic><topic>Male</topic><topic>Tumor Necrosis Factor-alpha - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deshpande, A. R.</creatorcontrib><creatorcontrib>Strobel, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deshpande, A. R.</au><au>Strobel, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2011-09</date><risdate>2011</risdate><volume>34</volume><issue>5</issue><spage>586</spage><epage>586</epage><pages>586-586</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21806647</pmid><doi>10.1111/j.1365-2036.2011.04778.x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2011-09, Vol.34 (5), p.586-586
issn 0269-2813
1365-2036
language eng
recordid cdi_proquest_miscellaneous_880998547
source Wiley
subjects Antibodies, Monoclonal - therapeutic use
Crohn Disease - diagnosis
Feces - chemistry
Female
Gastrointestinal Agents - therapeutic use
Humans
Leukocyte L1 Antigen Complex - metabolism
Male
Tumor Necrosis Factor-alpha - therapeutic use
title Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A55%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20Crohn%E2%80%99s%20disease%20relapse%20with%20faecal%20calprotectin%20in%20infliximab%20responders:%20a%20prospective%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Deshpande,%20A.%20R.&rft.date=2011-09&rft.volume=34&rft.issue=5&rft.spage=586&rft.epage=586&rft.pages=586-586&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2011.04778.x&rft_dat=%3Cproquest_pubme%3E880998547%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3698-d10f15bb772e054d985a838166fe9b49ba813e6b3eeb69fa02cad299ed02abaa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=880998547&rft_id=info:pmid/21806647&rfr_iscdi=true